Trial reportMultiple sclerosis and related disorders2024
Improvement in depressive symptoms is associated with sustained improvement in fatigue impact in adults with multiple sclerosis.
Trial report in Multiple sclerosis and related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Gender Differences and Comorbidities in Major Depression.Advances in experimental medicine and biology · 2026Review
- Self-reported quality of life related to cognitive function and fatigue in adults with multiple sclerosis.Multiple sclerosis and related disorders · 2025Article
- Linking Pathogenesis to Fall Risk in Multiple Sclerosis.Archives of internal medicine research · 2025Article
- Major depressive disorder in multiple sclerosis associated with differences in disease modifying therapy and demographics.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFatigue is one of the most common and disabling symptoms of multiple sclerosis (MS). Behavioral interventions that target one or more behaviors such as sleep hygiene, exercise, energy management, cognitive processes, as well as mood have been shown to reduce fatigue in people with MS. Yet, little is known about mechanisms of intervention effects on MS fatigue. Research suggests that depressive symptoms may be an important intervention target for improving MS fatigue. This study examined the association between pre- to post-intervention improvement in depressive symptoms and improvement in MS fatigue impact from pre-intervention through six months post-intervention.
methodsThis study is a secondary analysis of data from a randomized controlled trial comparing a fatigue self-management intervention to general MS education for improving fatigue in people with MS. Adults with MS (N = 218) were recruited for the parent trial from the Portland, Seattle, Baltimore, and North Florida/South Georgia VA Medical Centers, affiliated academic medical centers, and surrounding communities. Both study interventions showed similar efficacy, so participants were combined into one sample for this secondary analysis. Structural equation modeling was used to examine whether clinically significant change in depressive symptoms (a 17.5 % reduction in the total Beck Depression Inventory-II score) from pre- to post-intervention, was associated with improvement in fatigue impact on the physical, cognitive, and psychosocial subscales of the Modified Fatigue Impact Scale from pre-intervention through six-month follow-up.
resultsParticipants were predominantly female (72 %), middle-aged (M = 53.7 ± 10.1), and White (76 %) with a disease duration of 12.5 ± 8.4 years. Over half of the sample (58 %) had relapsing-remitting MS. Clinically significant improvement in depressive symptoms was associated with reduction in physical fatigue impact (β = -0.17, p = .004, 95 % CI [-0.28, -0.05]), cognitive fatigue impact (β = -0.20, p = .000, 95 % CI [-0.31, -0.10]), and psychosocial fatigue impact (β = -0.13, p = .03, 95 % CI [-0.25, -0.01]) through the six-month follow-up controlling for baseline depressive symptoms and fatigue impact, MS subtype (RRMS or Progressive MS), and income level. The model demonstrated adequate fit, χ2(6) = 12.747, p = .047, RMSEA = 0.072, CFI = 0.986, SRMR = 0.016, and accounted for 32 %, 39 %, and 28 % of the variance in physical, cognitive, and psychosocial fatigue impact respectively, which corresponded with large effect sizes.
conclusionThese findings, building on previous research, support the importance of reducing depressive symptoms for improving fatigue impact in people with MS. Future research should examine whether explicit focus on reducing depressive symptoms or related cognitive behavioral factors reduces fatigue in people with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.